CJC-1295 + Ipamorelin: Community Stack, DAC vs Non-DAC & Evidence
Community-reported stack, not an established clinical treatment.
What Is CJC-1295 + Ipamorelin?
The linked CJC-1295 ingredient profile covers DAC only. Products described as CJC-1295 without DAC are a separately described community variation, not an interchangeable identity or a linked canonical ingredient.
Handbook ingredient profiles
CJC-1295 with DAC + Ipamorelin
The CJC-1295 with DAC profile covers DAC only. The Handbook currently has no separate canonical profile for products described as CJC-1295 without DAC.
DAC and non-DAC community variations
The DAC and non-DAC forms are not interchangeable. The CJC-1295 with DAC profile and its research should not be read as describing products sold without DAC.
Why People Discuss This Stack
These are community-reported reasons for interest, not demonstrated effects of the combination.
- Muscle: Community discussions about muscle growth, lean mass and strength
- Recovery: Community discussions about exercise recovery
- Weight: Community discussions about fat loss and body composition
- Sleep: Community discussions about sleep quality, including mixed experiences
- Healthy Aging: Community discussions about anti-aging and longevity interests
Real-World Community Reports
Some people report combining Ipamorelin with CJC-1295 with DAC, while others report using products described as CJC-1295 without DAC.
These are community-reported practices, not established medical treatments. The DAC and non-DAC forms are not interchangeable, and experiences reported by individuals do not establish safety or effectiveness.
Ingredient-Level Evidence and Limitations
CJC-1295 with DAC
A placebo-controlled healthy-adult study found prolonged, dose-dependent increases in growth hormone and IGF-1 after CJC-1295 with DAC. That pharmacodynamic finding does not establish benefit for aging, body composition, athletic performance, or other clinical outcomes, and it must not be generalized to non-DAC products.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adultsIpamorelin
Preclinical research characterises ipamorelin as a selective growth-hormone secretagogue with minimal effects on cortisol and prolactin compared with older GHRPs.
Ipamorelin, the first selective growth hormone secretagogueOne prospective, randomized, controlled Phase II study evaluated ipamorelin for the management of postoperative ileus in bowel resection patients and did not establish significant efficacy versus placebo for that clinical endpoint. No large randomised outcome trials establish efficacy for age-related, body-composition, sleep, or performance claims.
Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patientsProducts described as CJC-1295 without DAC
The Handbook has no separate canonical profile or verified evidence summary for products described as CJC-1295 without DAC. The CJC-1295 with DAC study above must not be generalized to these products, and product labeling alone does not establish what a product contains.
Combination-Specific Evidence
The Handbook does not currently include verified combination-specific human evidence for CJC-1295 + Ipamorelin in either the DAC or non-DAC variation.
The ingredient studies cited on this page each evaluated a single ingredient. They do not establish the efficacy, safety, or synergy of combining CJC-1295 with DAC, or products described as CJC-1295 without DAC, with Ipamorelin.
Safety & Regulatory Context
Safety and regulatory information must be evaluated at the individual-ingredient level. This page does not assign an aggregate safety profile or regulatory status to the combination.
See the existing safety and regulatory context in the ingredient profiles: CJC-1295 with DAC + Ipamorelin. These ingredient sources do not establish the safety or efficacy of the combination.
The CJC-1295 with DAC profile does not describe the safety or regulatory context of products described as CJC-1295 without DAC, and that context remains uncertain here.